Bristol-Myers Squibb Company Princeton
C
reated in 1989 by the merger of New Jersey -based Squibb Corporation and New York-based Bristol-Myers, the company was selected for sustained development of quality health care products. Bristol Myers Squibb has developed major products for the treatment of cardiovascular problems, cancer, infectious diseases, central nervous system disorders, and is dermatological maladies, diagnostic agents, and women's health care products.
Bristol-Myers Squibb researchers were pioneers in the area of angiotensin converting enzyme inhibitors, a novel class antihypertensive agents. The synthesis of Captopril, the first orally active ACE inhibitor, established the key role of angiotensin in the mechanisms of hypertension and opened a fresh new field of research - ACE inhibition. Captopril has been sold as Capoten since 1981 and is one of the most successful drugs ever marketed. The company added a second ACE inhibitor, Monopril, in 1991.
Azactam, an antibacterial agent first marketed in 1987, represents a novel class of antibiotics known as monobactams. The invention of monobactams followed the design and implementation of a unique screen that isolated the bacteria's nucleus. In the 1950s and 1960s, the company made important contributions to the field of dermatology from its New Jersey laboratories.
Taxol, a promising anti-cancer drug effective against refractory ovarian cancer as well as breast and lung cancers, recently won approval by the FDA. Another drug in the field of infectious diseases is Videx, used in the treatment of AIDS.
Princeton is home to Bristol-Myers Squibb's U.S. Pharmaceutical Group and the company's research institute. For the past 15 years, the company has sponsored an Unrestricted Grants program which has provided more than 100 scientists with no-strings attached grants for biomedical research.
|
